Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.

The p53 regulatory network responds to cellular stresses by initiating processes such as cell cycle arrest and apoptosis. These responses inhibit cellular transformation and mediate the response to many forms of cancer therapies. Functional variants in the genes comprising this network could help id...

Full description

Bibliographic Details
Main Authors: Vazquez, A, Grochola, L, Bond, E, Levine, A, Taubert, H, Müller, T, Würl, P, Bond, G
Format: Journal article
Language:English
Published: 2010
_version_ 1797101594981957632
author Vazquez, A
Grochola, L
Bond, E
Levine, A
Taubert, H
Müller, T
Würl, P
Bond, G
author_facet Vazquez, A
Grochola, L
Bond, E
Levine, A
Taubert, H
Müller, T
Würl, P
Bond, G
author_sort Vazquez, A
collection OXFORD
description The p53 regulatory network responds to cellular stresses by initiating processes such as cell cycle arrest and apoptosis. These responses inhibit cellular transformation and mediate the response to many forms of cancer therapies. Functional variants in the genes comprising this network could help identify individuals at greater risk for cancer and patients with poorer responses to therapies, but few such variants have been identified as yet. We use the NCI60 human tumor cell line anticancer drug screen in a scan of single nucleotide polymorphisms (SNP) in 142 p53 stress response genes and identify 7 SNPs that exhibit allelic differences in cellular responses to a large panel of cytotoxic chemotherapeutic agents. The greatest differences are observed for SNPs in 14-3-3tau (YWHAQ; rs6734469, P=5.6x10(-47)) and CD44 (rs187115, P=8.1x10(-24)). In soft-tissue sarcoma patients, we find that the alleles of these SNPs that associate with weaker growth responses to chemotherapeutics associate with poorer overall survival (up to 2.89 relative risk, P=0.011) and an earlier age of diagnosis (up to 10.7 years earlier, P=0.002). Our findings define genetic markers in 14-3-3tau and CD44 that might improve the treatment and prognosis of soft-tissue sarcomas.
first_indexed 2024-03-07T05:54:05Z
format Journal article
id oxford-uuid:e9e958d5-1232-4664-97af-871a6d25eeaf
institution University of Oxford
language English
last_indexed 2024-03-07T05:54:05Z
publishDate 2010
record_format dspace
spelling oxford-uuid:e9e958d5-1232-4664-97af-871a6d25eeaf2022-03-27T10:57:45ZChemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e9e958d5-1232-4664-97af-871a6d25eeafEnglishSymplectic Elements at Oxford2010Vazquez, AGrochola, LBond, ELevine, ATaubert, HMüller, TWürl, PBond, GThe p53 regulatory network responds to cellular stresses by initiating processes such as cell cycle arrest and apoptosis. These responses inhibit cellular transformation and mediate the response to many forms of cancer therapies. Functional variants in the genes comprising this network could help identify individuals at greater risk for cancer and patients with poorer responses to therapies, but few such variants have been identified as yet. We use the NCI60 human tumor cell line anticancer drug screen in a scan of single nucleotide polymorphisms (SNP) in 142 p53 stress response genes and identify 7 SNPs that exhibit allelic differences in cellular responses to a large panel of cytotoxic chemotherapeutic agents. The greatest differences are observed for SNPs in 14-3-3tau (YWHAQ; rs6734469, P=5.6x10(-47)) and CD44 (rs187115, P=8.1x10(-24)). In soft-tissue sarcoma patients, we find that the alleles of these SNPs that associate with weaker growth responses to chemotherapeutics associate with poorer overall survival (up to 2.89 relative risk, P=0.011) and an earlier age of diagnosis (up to 10.7 years earlier, P=0.002). Our findings define genetic markers in 14-3-3tau and CD44 that might improve the treatment and prognosis of soft-tissue sarcomas.
spellingShingle Vazquez, A
Grochola, L
Bond, E
Levine, A
Taubert, H
Müller, T
Würl, P
Bond, G
Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.
title Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.
title_full Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.
title_fullStr Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.
title_full_unstemmed Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.
title_short Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.
title_sort chemosensitivity profiles identify polymorphisms in the p53 network genes 14 3 3tau and cd44 that affect sarcoma incidence and survival
work_keys_str_mv AT vazqueza chemosensitivityprofilesidentifypolymorphismsinthep53networkgenes1433tauandcd44thataffectsarcomaincidenceandsurvival
AT grocholal chemosensitivityprofilesidentifypolymorphismsinthep53networkgenes1433tauandcd44thataffectsarcomaincidenceandsurvival
AT bonde chemosensitivityprofilesidentifypolymorphismsinthep53networkgenes1433tauandcd44thataffectsarcomaincidenceandsurvival
AT levinea chemosensitivityprofilesidentifypolymorphismsinthep53networkgenes1433tauandcd44thataffectsarcomaincidenceandsurvival
AT tauberth chemosensitivityprofilesidentifypolymorphismsinthep53networkgenes1433tauandcd44thataffectsarcomaincidenceandsurvival
AT mullert chemosensitivityprofilesidentifypolymorphismsinthep53networkgenes1433tauandcd44thataffectsarcomaincidenceandsurvival
AT wurlp chemosensitivityprofilesidentifypolymorphismsinthep53networkgenes1433tauandcd44thataffectsarcomaincidenceandsurvival
AT bondg chemosensitivityprofilesidentifypolymorphismsinthep53networkgenes1433tauandcd44thataffectsarcomaincidenceandsurvival